Neovacs teams up with 3P

Just recently, Neovacs had acquired the technology for producing IFNα from Amegabiotech. The new license agreement will allow Neovacs to directly transfer the new tech to 3P’s production site. There, it will ensure the manufacture of the IFNα cytokine, which is a key component of Neovacs’ IFN Kinoid, a therapeutic vaccine composed of the targeted cytokine IFNα conjugated with a carrier protein, Keyhole Limpet Hemocyanin.

Miguel Sieler, CEO of Neovacs, said, “This partnership is in line with the recent license agreement signed with AMEGABIOTECH. The completion of these two steps allows us to secure the complete production chain for the manufacture of IFNα, one of the primary raw materials of our most advanced product, IFNα Kinoid. In addition, the agreement complements the partnership signed earlier this year with Stellar Biotechnologies, the supplier of the other main component of our vaccine IFNα Kinoid, Keyhole Limpet Hemocyanin (KLH). Within the framework of this partnership, Stellar Biotechnologies holds 30% of Neostell, the production subsidiary of Neovacs.”

Elena Erroba, Business Development Director of 3P Biopharmaceuticals - the only Spanish manufacturer of biological products in the healthcare field - added: “3P Biopharmaceuticals is very happy with this collaboration. It will allow 3P Biopharmaceuticals to contribute to a very innovative therapeutic approach, with our strong competence in the field of manufacturing high quality protein.”